General Critical Care

A new a agent (MV140: a sublingual preparation of whole-cell inactivated bacteria) was studied in a controlled trial of modest size and duration, and showed promising clinical efficacy in reducing recurrent UTI in women suffering from this condition.

https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2100018